Mineralys Therapeutics (NASDAQ: MLYS) presented clinical data from its Phase 3 Launch-HTN trial showing lorundrostat reduced blood pressure in participants ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE